Newsroom
- June 17, 2026
MEDIA ADVISORY: APA and APA Foundation to Honor Mental Health Advocate Bebe Moore Campbell with Summer Events, Sixth Annual 5K Run and 1 Mile Fun Walk & Roll
APA MOORE Equity in Mental Health Initiative, a collection of community-wide events focused on youth mental health equity through education, outreach, and advocacy named in honor of Bebe Moore Campbell, a staunch mental health advocate and award-winning author, who worked tirelessly to shed light on the mental health needs of communities of color. In 2008, the U.S. House of Representatives announced July as Bebe Moore Campbell National Minority Mental Health Awareness Month. At APA, the celebration continues this summer.
- June 17, 2026
- Español
AVISO PARA MEDIOS: APA y la Fundación de la APA rendirán homenaje a la defensora de la salud mental Bebe Moore Campbell con eventos de verano, la sexta carrera anual 5K y una caminata recreativa de 1 milla
En 2021, la Asociación Psiquiátrica Americana lanzó la Iniciativa MOORE para la Equidad en la Salud Mental, una serie de eventos comunitarios enfocados en promover la equidad en la salud mental de niños, adolescentes y jóvenes a través de la educación, el alcance comunitario y la defensa de políticas públicas.
- June 01, 2026
June 2026 Issues of APA Journals Feature New Research on Treating Severe Depression, Treatments for Suicide Risk, Integrated Behavioral Health Care, and More
The latest issues of two American Psychiatric Association journals (The American Journal of Psychiatry and Psychiatric Services) are now available online.
- May 20, 2026
Mark Rapaport, M.D., Assumes Office as APA President
Mark Rapaport, M.D., began his one-year term as president of the American Psychiatric Association at the close of APA’s 2026 Annual Meeting in San Francisco.
- May 19, 2026
New Research Finds Low-Dose Buprenorphine May Help Sustain Ketamine’s Benefits for Suicidal Ideation
New research published online today in the American Journal of Psychiatry finds that low-dose buprenorphine, given after a single ketamine infusion, significantly sustained reductions in suicidal ideation in adults with major depressive disorder. The randomized, double-blind, placebo-controlled trial is the first to show that a pharmacologic intervention may help maintain and build on ketamine’s anti-suicidal effects in this at-risk population.